These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26299750)

  • 81. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
    LeBlanc R; Vasquez Y; Hannaman D; Kumar N
    Vaccine; 2008 Jan; 26(2):185-92. PubMed ID: 18054817
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Disulfide bond mapping of Pfs25, a recombinant malaria transmission blocking vaccine candidate.
    Lee SM; Plieskatt J; King CR
    Anal Biochem; 2018 Feb; 542():20-23. PubMed ID: 29162427
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
    Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Simons LM; Ferrer P; Gombakomba N; Underwood K; Herrera R; Narum DL; Canepa G; Acquah F; Amoah L; Duffy PE; Barillas-Mury C; Long C; Lee SM; Locke E; Miura K; Williamson KC
    Vaccine; 2023 May; 41(21):3367-3379. PubMed ID: 37100721
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
    Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
    Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity.
    Chan JA; Wetzel D; Reiling L; Miura K; Drew DR; Gilson PR; Anderson DA; Richards JS; Long CA; Suckow M; Jenzelewski V; Tsuboi T; Boyle MJ; Piontek M; Beeson JG
    PLoS One; 2019; 14(9):e0221733. PubMed ID: 31504038
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate.
    Lee SM; Wu Y; Hickey JM; Miura K; Whitaker N; Joshi SB; Volkin DB; Richter King C; Plieskatt J
    Malar J; 2019 Nov; 18(1):356. PubMed ID: 31703583
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
    Favuzza P; Blaser S; Dreyer AM; Riccio G; Tamborrini M; Thoma R; Matile H; Pluschke G
    Malar J; 2016 Mar; 15():161. PubMed ID: 26979066
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice.
    Brod F; Miura K; Taylor I; Li Y; Marini A; Salman AM; Spencer AJ; Long CA; Biswas S
    Front Immunol; 2018; 9():2780. PubMed ID: 30564231
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Transmission-blocking vaccines: uses and current status of development.
    Kaslow DC
    Int J Parasitol; 1997 Feb; 27(2):183-9. PubMed ID: 9088989
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase.
    Merino KM; Bansal GP; Kumar N
    Immunology; 2016 Aug; 148(4):433-47. PubMed ID: 27177843
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.
    Gregory JA; Li F; Tomosada LM; Cox CJ; Topol AB; Vinetz JM; Mayfield S
    PLoS One; 2012; 7(5):e37179. PubMed ID: 22615931
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells.
    Milek RL; DeVries AA; Roeffen WF; Stunnenberg H; Rottier PJ; Konings RN
    Exp Parasitol; 1998 Oct; 90(2):165-74. PubMed ID: 9769246
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Recent advances in recombinant protein-based malaria vaccines.
    Draper SJ; Angov E; Horii T; Miller LH; Srinivasan P; Theisen M; Biswas S
    Vaccine; 2015 Dec; 33(52):7433-43. PubMed ID: 26458807
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Refolding and characterization of a diabody against Pfs25, a vaccine candidate of Plasmodium falciparum.
    Jagannath DK; Valiyaparambil A; Viswanath VK; Hurakadli MA; Kamariah N; Jafer AC; Patole C; Pradhan S; Kumar N; Lakshminarasimhan A
    Anal Biochem; 2022 Oct; 655():114830. PubMed ID: 35944694
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunogenicity of Plasmodium falciparum sexual stage antigens: implications for the design of a transmission blocking vaccine.
    Kaslow DC
    Immunol Lett; 1990 Aug; 25(1-3):83-6. PubMed ID: 1704352
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
    Qian F; Rausch KM; Muratova O; Zhou H; Song G; Diouf A; Lambert L; Narum DL; Wu Y; Saul A; Miller LH; Long CA; Mullen GE
    Vaccine; 2008 May; 26(20):2521-7. PubMed ID: 18423804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.